TSX Venture Exchange: ARI
TORONTO, Sept. 20 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced
today that it has been selected to present the company and its business model
at the 11th Technology Summit and Technology Platform - BioPartnering Session
in New Delhi, September 22, 2005. ARIUS will also participate in partnering
events organized by the Canadian Embassy. The Company will discuss its
anticancer antibody FunctionFIRST(TM) platform and licensing candidates to an
audience of Indian Biotech and technology companies.
Dr. David S. Young, President and Chief Scientific Officer of ARIUS,
commented, "India is an important emerging market for biotech. We are working
to increase the exposure of the Company and will be seeking partners who can
provide cost effective services and expertise to support our own research
efforts."
About ARIUS Research
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline of over 300
functional MAbs, which may be used for commercial collaborations, out-
licensing or in-house development. ARIUS has ongoing licensing and research
partnerships with key biotechnology and drug development companies that
provide revenues and access to external technologies. The long-term vision of
ARIUS is to deliver personalized therapy by matching multiple antibodies to
the distinct antigenic characteristics of each patient's tumour cells thereby
increasing efficacy and avoiding side effects.
Web site: www.ariusresearch.com
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Published Sep 20 2005
5 min read